CN113355391A - Method for establishing database by targeting FFPE RNA - Google Patents
Method for establishing database by targeting FFPE RNA Download PDFInfo
- Publication number
- CN113355391A CN113355391A CN202110627190.XA CN202110627190A CN113355391A CN 113355391 A CN113355391 A CN 113355391A CN 202110627190 A CN202110627190 A CN 202110627190A CN 113355391 A CN113355391 A CN 113355391A
- Authority
- CN
- China
- Prior art keywords
- ffpe rna
- primer
- targeted
- rna
- ffpe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000008685 targeting Effects 0.000 title description 5
- 102100034343 Integrase Human genes 0.000 claims abstract description 29
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims abstract description 29
- 238000012163 sequencing technique Methods 0.000 claims abstract description 24
- 108091034057 RNA (poly(A)) Proteins 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 239000002299 complementary DNA Substances 0.000 claims abstract description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 20
- 230000003321 amplification Effects 0.000 claims description 20
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 20
- 238000010804 cDNA synthesis Methods 0.000 claims description 19
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 12
- 101710124239 Poly(A) polymerase Proteins 0.000 claims description 12
- 238000007403 mPCR Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000011144 upstream manufacturing Methods 0.000 claims description 11
- 238000003752 polymerase chain reaction Methods 0.000 claims description 9
- 239000011535 reaction buffer Substances 0.000 claims description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims 2
- 239000003161 ribonuclease inhibitor Substances 0.000 claims 2
- 238000010276 construction Methods 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000013467 fragmentation Methods 0.000 description 17
- 238000006062 fragmentation reaction Methods 0.000 description 17
- 239000011324 bead Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 101150008921 Brca2 gene Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108700010154 BRCA2 Genes Proteins 0.000 description 3
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000052609 BRCA2 Human genes 0.000 description 2
- 108700020462 BRCA2 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001921 locked nucleotide group Chemical group 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 241000264288 mixed libraries Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a method for targeted FFPE RNA library construction, which comprises the following steps: fragmenting the FFPE RNA of the sample to ensure that the size of the FFPE RNA is mainly concentrated to 150-200 bp; adding poly (A) polynucleic acid at the end of the fragmented FFPE RNA; using reverse transcriptase and taking FFPE RNA with A added at the tail end as a template to synthesize 1st cDNA; carrying out enrichment treatment on the genes in the target region on the synthesized 1st cDNA; and (4) amplifying the library. The method directly amplifies a target region on 1st cDNA by using a specific primer with a linker sequence, then realizes a complete sequencing library through PCR, and directly amplifies, builds and sequences the target region, so that the target region is more concentrated, and the library building process is simpler, the time is short, the data utilization rate is high, and the cost is low.
Description
Technical Field
The invention relates to a method for constructing a targeted FFPE RNA library.
Background
FFPE samples of tumor tissues after formalin fixation and wax block embedding are important resources for clinical research, can be used for histological diagnosis, and can also be used for performing NGS sequencing analysis on information such as gene expression, alternative splicing fusion genes and the like. However, formalin and protein cross-linking affect the extraction of nucleic acid, inhibit the activity of polymerase and the like, and paraffin infiltrated at high temperature can reduce the quality of nucleic acid. Furthermore, RNA is more easily degraded than DNA, so that FFPE RNA has poor integrity and low quality. About 90% of total RNA is ribosomal RNA (rrna), and thus RNA-seq of FFPE RNA samples presents a serious challenge.
The RNA-seq library construction strategy for the FFPE RNA sample is generally long, about 8-10 hours, rRNA is removed, and then the processes of RNA fragmentation, 1st cDNA synthesis, 2nd cDNA synthesis, end repair, linker connection, library amplification and the like are complicated. Capture sequencing is also typically performed to obtain the genetic information desired by the researcher, and therefore higher sequencing throughput is required. The database building strategy is long in time consumption and high in cost, and has high requirements on the quality, the input amount and the like of the sample.
Disclosure of Invention
The invention aims to provide a method for targeted FFPE RNA library construction, which can realize a library construction strategy for FFPE RNA with lower quality and less initial quantity.
The technical scheme adopted by the invention is as follows: a method for targeted FFPE RNA banking comprising the steps of:
(1) fragmenting FFPE RNA;
(2) adding poly (A) polynucleic acid to the 3' end of the fragmented FFPE RNA;
(3)1stsynthesizing cDNA;
(4) enrichment and amplification of the target region gene;
(5) and (4) amplifying the library.
Preferably, the FFPE RNA fragmentation in step (1) is performed using Mg2+Different degrees of fragmentation were performed.
More preferably, the different degrees of fragmentation of the FFPE RNA in step (1) are achieved by using the length of incubation at high temperature to achieve different qualitative measures of fragmentation of the FFPE RNA.
Preferably, poly (A) polymerase is used as the 3' end of the FFPE RNA fragmented in step (2) and the poly (A) polynucleic acid is added.
More preferably, the 3' end of the segmented FFPE RNA in step (2) is added with poly (A) polynucleic acid reaction program: adding 27-33 poly (A) at the end in 10min at 37 ℃.
More preferably, the 3' end of the FFPE RNA fragmented in step (2) is added with poly (A) polynucleic acid reaction buffer: 1 XPoly (A) Polymerase Reaction Buffer was 50mM Tris-HCl, 250mM NaCl, 10mM MgCl2, pH 8.1.
Preferably, the synthesis system of 1st cDNA in step (3) comprises: FFPE RNA fragment, buffer, dNTP, Oligo-dt30v Primer, T-Primer and reverse transcriptase obtained in the step (2), wherein the Oligo-dt30v Primer sequence is as follows: 5 '-AAGCAGTGGTATCAACGCAGAGTACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTV-3', T-Primer sequence: 5 '- -AAGCAGTGGTATCAACGCAGAGAATCATRGGrG + G-3'. Locked nucleic acid modification of T-Primer primers can increase the terminal transfer capability of reverse transcriptase.
Preferably, the reverse transcriptase used in the 1st cDNA synthesis system in step (3) isIV Reverse Transcriptase or ⅢReverse Transcriptase。
Preferably, the 5 × RT Buffer used in the 1st cDNA synthesis system in step (3) is: 250mM Tris-HCl, 375mM KCl, 28mM MgCl2, pH 7.9.
Preferably, the step (4) is specifically: carrying out upstream specific primer design on a targeted gene, and then carrying out multiplex PCR (polymerase chain reaction) by utilizing an upstream specific primer and a downstream primer to realize amplification and enrichment of a targeted region gene, wherein the upstream specific primer is designed to be composed of a joint sequence and a specific primer, the joint primer is a sequencing primer of a sequencing platform, and the design principle of the specific primer is as follows: the length is 15-30nt, the number of continuous bases is not more than 3, the GC content is 35% -65%, the Tm value is 55-63 ℃, and the Tm of part of special regions is slightly higher or lower; the primer does not contain a self-complementary sequence, has no obvious secondary structure, and has an interval of adjacent primer recognition sites of more than 40bp and less than 100 bp; the sequence of the downstream primer is as follows: 5 '-AAGCAGTGGTATCAACGCAGAGTNNNGNNCNNNGATCGGAAGAGCACACGTCTGAAC TCCAGTC-3', wherein TNNNGNNCNNN is a UMI tag.
Preferably, the amplification enzyme used in step (4) is: 2 x HieffHG Multiplex PCR Master Mix 2 × high GC Multiplex PCR premix (assist in san, Cat.13283), can be compatible with Multiplex gene amplification with GC content of about 25% -70%, can be quickly and conveniently used for Multiplex PCR reaction, and has the characteristics of high uniformity, high specificity and high sensitivity.
Preferably, the method for targeted FFPE RNA banking according to claim 1, characterized in that: the library-amplifying enzyme used in step (5) was 2 XsuperII High-Fidelity Mix for Library Amplification (assist in san, Cat.12621), no preference, with High Amplification efficiency.
The invention has the beneficial effects that:
(1) the method increases the tolerance to the quality of the FFPE RNA, and can realize the library construction and sequencing of various samples;
(2) the method increases the selectivity of the input amount of the FFPE RNA, and can realize the library construction and sequencing of samples with different input amounts;
(3) the method directly amplifies a target region on 1st cDNA by using a specific primer with a UMI adapter sequence, then realizes a complete sequencing library through PCR, and directly amplifies, builds and sequences the target region so as to centralize the target region, and has the advantages of simpler library building process, short time, high data utilization rate and low cost.
Drawings
FIG. 1 principle of a method for targeted FFPE RNA banking.
FIG. 2 RNA fragment 3' end plus A capability test.
FIG. 3cDNA Peak Pattern analysis.
FIG. 4 FFPE RNA Peak type analysis.
FIG. 5 library peak pattern analysis.
FIG. 6 sequencing library sequencing data analysis.
FIG. 7 coverage of BACA2 gene region.
Detailed Description
The following further describes the embodiments of the present invention with reference to the drawings.
Example 1 method for targeting FFPE RNA Bank construction
1.1, using RNeasy FFPE Kit (Qiagen, Cat.73504), the paraffin section sample of the tumor tissue was subjected to FFPE RNA extraction, and the quality of the extracted FFPE RNA was judged according to the 2100 bioanalyzer RNA 6000 Pico total RNA analysis chip. The FFPE RNA was then fragmented to varying degrees. DV (distance vector)200Representing the proportion of RNA fragments larger than 200nt in the sample, DV for the FFPE RNA sample with serious degradation200The values are better able to reflect the quality of the sample. Thus according to different DV200The FFPE RNA was fragmented as shown in Table 1. After high-temperature treatment of different degrees, the size of the FFPE RNA is concentrated to 150-200 bp, and the fragmentation of the FFPE RNA is completed.
TABLE 1 fragmentation conditions for different quality FFPE RNAs
DV200 | Fragmentation conditions |
≥70% | 94℃10min |
50%~70% | 94 |
20%~50% | 85℃8min |
≤20% | 65℃5min |
1.2 adding polynucleic acid to fragmented RNA, thereby increasing the utilization of the template. Examples of polymerases that add polynucleic acids to the template include Poly (A) polymerase, Poly (U) polymerase. The ability to add A to the 3' end of RNA for Poly (A) polymerase is critical for efficient template utilization. Thus, using a 150bp RNA RN1 sequence: 5'-TACCTGGTTGATCCTGCCAGTAGCATATGCTTGTCTCAAAGATTAAGCCATGCATGTCTAAGTACGCACGGCCGGTACAGTGAAACTGCGAATGGCTCATTAAATCAGTTATGGTTCCTTTGGTCGCTCGCTCCTCTCCTACTTGGATAA-3', the efficiency of adding A at the 3 ' end of RNA was tested using Poly (A) polymerase from NEB. As shown in FIG. 2, it was found that the use of 5U of Poly (A) Polymerase in a 1X Poly (A) Polymerase Reaction Buffer (50mM Tris-HCl, 250mM NaCl, 10mM MgCl2, pH 8.1@25 ℃) system allows for efficient addition of Poly (A) of different lengths at different Reaction times. 1ug of RN1 template was tested for the ability to add A at the ends of 10min, 20min and 30min in the reaction system shown in Table 2 below, and it was found that 10min of reaction was performed at 30 deg.C, about 50 poly (A) s could be added at the end of RN 13 ', about 100 poly (A) s could be added at the end of RN 13 ' for 20min, and about 150 poly (A) s could be added at the end of RN 13 ' for 30 min. Therefore, considering that about 30 (27-33) poly (A) s are required for 1st cDNA synthesis, the optimal experimental condition determined by the invention is reaction at 37 ℃ for 10min to complete the addition of poly (A) at the 3' end of RNA.
TABLE 2 RNA 3' end plus A reaction System
Components | Fragmentation conditions |
RN1 | 1μg |
5X Poly(A)Polymerase Reaction Buffer | 4μL |
ATP(10mM) | 2μL |
Poly(A)PolymeRase | 1μL |
DEPC-H2O | / |
Total volume | 20μL |
1.3, after A is added at the tail end of the fragmented FFPE RNA, reverse transcription of various sample RNAs is completed by utilizing a high-efficiency 1st cDNA synthesis reaction system. In the 1st cDNA synthesis of the present invention, the full-length cDNA is synthesized using the DNA polymerase activity and terminal transferase activity (Template Switch) of reverse transcriptase. The efficiency of 8 reverse transcriptases used for cDNA synthesis was tested.
S1: invitrogen SuperScript II reverse transcriptase (Cat.18064022)
S2: invitrogen SuperScript III reverse transcriptase (Cat.18080044)
S3: maxima H Minus reverse transcriptase (Thermo, Cat.18064022)
S4:EnzScriptTM(MMLV Reverse Transcriptase RNase H-) (praise, Cat. P7600L)
S5:II Reverse Transcriptase second generation thermostable Reverse Transcriptase (assist in san, Cat.11110)
S6:III Reverse Transcriptase third Generation Heat-resistant Reverse Transcriptase (assist in san, Cat.11111)
S7:IV Reverse Transcriptase fourth generation thermostable Reverse Transcriptase (assist in san Francisco, Cat.11112)
S8:V Reverse Transcriptase fifth generation thermostable Reverse Transcriptase (assist in san Francisco, Cat.11300).
First, the DNA polymerase activity and terminal transferase activity (Template Switch) of the above 8 reverse transcriptases were tested. As the test conditions are shown in Table 3, it can be seen that the DNA polymerase activity and terminal transferase activity (Template Switch) of different reverse transcriptases are different, and the higher the yield, the stronger the polymerase activity and the Template Switch. There was essentially no bias according to the cDNA peak pattern analysis of FIG. 3. According to the sequencing data analysis of Table 4, the sequencing difference is mainly expressed in rRNA residual rate, so that the preferential selection is madeIV Reverse Transcriptase fourth generation thermostable Reverse Transcriptase (assist in san, Cat.11112) in 1st cDNA synthesis system, high yield, normal cDNA peak pattern, sequencing data show that Mapping Rate is normal, and rRNA residue is less.
TABLE 3 polymerization Capacity and template Switch Capacity test of different reverse transcriptases
TABLE 4 sequencing differential analysis of different reverse transcriptases
Secondly, the reaction Buffer, T-Primer, Oligo-dt30v Primer dosage and the like of the 1st cDNA synthesis system also have great correlation to the cDNA synthesis efficiency. The invention optimally combines a set of reaction systems: 5 × RT Buffer (250mM Tris-HCl, 375mM KCl, 28mM MgCl2, pH 7.9@25 ℃); oligo-dt30v primer sequence, 5 ' -AAGCAGTGGTATCAACGCAGAGTACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTV-3 ', 20pmol usage, 3 ' end non-T primer increased randomness; T-Primer sequence, 5 '-AAGCAGTGGTATCACGCAGAGTACATrGrGrGr + G-3', 50pmol usage amount, locked nucleotide modification can increase Template Switching ability; the reaction program is 42, 90 min; 15min at 70 ℃; hold at 4 ℃. The working system of the present invention can complete the synthesis of 1st cDNA of RNA of 10pg to 1. mu.g.
1.4 the present invention utilizes 2 Hieff of Hippoff, Inc., St.John, Hippo, Ltd, by designing an upstream specific primer for a target geneHG Multiplex PCR Master Mix 2 Xhigh GC Multiplex PCR premix (assist in san, Cat.13283) for amplification enrichment of the targeted region. Wherein the specific primer consists of an adaptor sequence and the specific primer. Taking BRCA2 gene as an example, the upstream amplification primers in Table 5 are designed, wherein the upstream sequence consists of a sequencing sequence of an illumina sequencing platform and specific primers on genes, and the principle of designing the primers is as follows: the length is 15-30nt, the number of continuous bases is not more than 3, the GC content is 35% -65%, the Tm value is 55-63 ℃, and the Tm of part of special regions is slightly higher or lower; the primer does not contain self-complementary sequences and has no obvious secondary structure; adjacent primer recognition site spacing>40 and<100, when the capture rate is too low, the specific region is easily captured repeatedly, and when the capture rate is too high, the capture is missed in the middle region; preferably, about 10 bases after the primer do not match to other positions in the genome, and the specificity is high. The downstream Primer IS composed of IS Primer,10bpThe sequence composition of the UMI sequence and the sequencing sequence of the illumina sequencing platform, and the primer structure is shown in Table 5.
TABLE 5 upstream primer sequences of BRCA2
Taking BRCA2-F1 as an example, the sequence is as follows: 5'-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGGCGCGAGCTTCTGA-3' are provided.
1.5 library amplification by high fidelity, unbiased polymerase, 2 XSuperII High-Fidelity Mix for Library Amplification (assist in san, Cat.12621) was performed.
Example 2 library application test targeting BRCA2 Gene with four different qualitative measures of FFPE RNA
2.1 quality control of FFPE RNA:
extraction of FFPE RNA was performed using the neosy FFPE Kit (Qiagen, cat.73504) Kit. The invention quickly extracts FFPE RNA from 4 different paraffins of breast cancer, and then judges the quality of the extracted FFPE RNA by using a 2100 bioanalyzer RNA 6000 Pico total RNA analysis chip, and the result is shown in FIG. 4. Judging the quality measure DV of four samples 1#, 2#, 3#, 4# according to FIG. 420074%, 54%, 21%, 11%, respectively.
2.2 fragmentation of FFPE RNA:
the high temperature fragmentation of Table 6 was performed based on four different quality samples FFPE RNA, 50ng was added to each sample, 1# -4# in Table 7, and high temperature Mg was used2+Fragmentation was performed, and the RNA size was all concentrated to about 150-200 bp in the present invention using a commercial fragmentation reagent 2 XFrag/Primer Buffer from assist in, Inc. (assist in, Cat # 11377).
TABLE 6 fragmentation of sample RNA
Sample numbering | DV200 | Fragmentation conditions |
1# | 74% | 94 |
2# | 54% | 94 |
3# | 21% | 85 |
4# | 21% | 65℃5min |
TABLE 7 fragmentation of sample RNA
Addition of components | Addition system |
FFPE RNA | 8.5μL(50ng) |
2×Frag/Primer Buffer | 8.5μL |
Total volume | 17μL |
2.3 addition of A to the 3' end of fragmented FFPE RNA:
the addition of poly (A) to the 3 'end of the fragmented FFPE RNA was completed by performing an addition reaction of A to the 3' end of the fragmented FFPE RNA using Poly (A) polymerase from NEB under the reaction conditions of 37 ℃ for 10min as shown in Table 8.
TABLE 8 terminal-addition reaction of fragmented RNA
Addition of components | Addition system |
Fragmented FFPE RNA | 17μL |
5X Poly(A)Polymerase Reaction Buffer | 5μL |
ATP(10mM) | 2μL |
Poly(A)PolymeRase | 1μL |
Total volume | 25μL |
2.41 st cDNA Synthesis:
using the combined 1st cDNA synthesis system of the present invention, 1# -4# samples were subjected to cDNA synthesis and Template Switch conversion, as shown in Table 9, under the following reaction conditions: hold at 42 ℃ for 90min, 70 ℃ for 15min and 4 ℃ to complete 1st cDNA synthesis.
Watch 91stcDNA Synthesis System
2.5 enrichment of the targeting region:
by using 2 x HieffHG Multiplex PCR Master Mix 2 Xhigh GC Multiplex PCR premix (assist in san, Cat.13283) was used for amplification enrichment of the BRCA2 gene in the target region, 104 specific primers in the upstream were mixed to 1. mu.M of the Primer Panel constituting BRCA2, and the IS-T7 Primer in the downstream was diluted to 50. mu.M for use. The reaction system is shown in Table 10, and the reaction procedure is shown in Table 11, to complete the enrichment of the targeted region.
TABLE 10 enrichment reaction System for Targeted regions
TABLE 11 enrichment reaction conditions for the target region
After the reaction, 1ul of Exonaclease I (NEB, Cat. M0293) was added, the reaction was carried out at 37 ℃ for 10min, and then magnetic bead purification of the enriched region was carried out.
2.6 magnetic bead purification of enriched library:
using Hieff commercially available from this companyRNA Cleaner (assist in san, Cat.12601), 1.0 magnetic bead purification of fragmented 3' plus A FFPE RNA, was performed as follows:
1) preparation work: will HieffThe DNA Selection Beads (Yeasen Cat #12601) Beads were removed from the freezer and allowed to equilibrate at room temperature for at least 30 min. Preparing 80% ethanol by using nucleic free H2O;
2) vortex and oscillate or fully reverse the magnetic beads to ensure full mixing;
3) aspirate 50. mu.L of HieffRNA Cleaner (1.0X, Beads: DNA 1.0:1) to the product of the last step, pipette well and blow and mix, incubate for 5min at room temperature;
4) the PCR tube was placed in a magnetic rack to separate the beads from the liquid, and after the solution was clarified (about 5min), the supernatant was carefully removed;
5) keeping the PCR tube in a magnetic frame all the time, adding 200 μ L of clean free H2O freshly prepared 80% ethanol to rinse the magnetic beads, incubating at room temperature for 30sec, and carefully removing the supernatant;
6) repeating the step 5), rinsing twice in total, and sucking out residual liquid by using a 10 mu L pipette;
7) keeping the PCR tube in a magnetic frame all the time, and opening a cover to dry the magnetic beads at room temperature (5-10 min);
8) DNA elution: taking down the PCR tube from the magnetic frame, adding 22 microliter ddH20, gently blowing and beating by using a pipette until the mixture is fully and uniformly mixed, and standing for 5min at room temperature;
9) the PCR tube was centrifuged briefly and placed in a magnetic stand and left to stand until the solution cleared (about 3min), 20. mu.L of the supernatant was carefully removed to a new nucleic free PCR tube for RNA fragmentation.
2.7 library amplification:
the working company has commercialized 2 × SuperII High-Fidelity Mix for Library Amplification (assist in san, Cat.12621) was performed. The reaction system is shown in Table 12, and the reaction procedure is shown in Table 13. After the library amplification, 0.9 Xmagnetic bead purification of the library was performed, as in the 2.6 magnetic bead purification step, finally 22. mu.L of ddH20 eluted magnetic beads, 20. mu.L of supernatant was taken for the determination of the concentration of the Qubit 3.0 library, and the results are shown in Table 14, Qsep 100 analysis library peak diagram is shown in FIG. 5, the main peak of the library is about 280bp, and the insert is about 150 bp.
TABLE 12 library amplification reaction System
TABLE 13 library amplification reaction conditions
TABLE 14 library yields
Experiment number | Library concentration (ng/ul) | Library yield (ng) |
M1-1# | 35.2 | 704 |
M2-2# | 30.5 | 610 |
M3-3# | 20.3 | 406 |
M4-4# | 10.1 | 202 |
2.8 sequencing data analysis:
and (3) carrying out Novaseq6000 sequencing analysis on four libraries, namely M1-M4(1# -4#), which are subjected to equal-mass mixed library and sent to a Nuo grass origin Illumina platform. The sequencing quality, the data uniformity, the coverage of the target region and other aspects are analyzed, as shown in FIGS. 5 and 6, the sequencing quality is better, the library data is uniform, the coverage of the BACA2 gene region is better, and the diagnosis requirement can be met.
Claims (11)
1. A method for targeted FFPE RNA banking comprising the steps of:
(1) fragmenting FFPE RNA;
(2) poly (a) polynucleic acid is added to the 3' end of the fragmented FFPE RNA;
(3)1stsynthesizing cDNA;
(4) enrichment and amplification of the target region gene;
(5) and (4) amplifying the library.
2. The method for targeted FFPE RNA banking of claim 1 wherein: and (1) fragmenting the FFPE RNA, namely fragmenting the FFPE RNA to 150-200 bp.
3. The method for targeted FFPE RNA banking of claim 2 wherein: poly (a) is added to the 3' -end of the FFPE RNA fragmented in step (2) and poly (a) polymerase is used as the polynucleic acid.
4. The method for targeted FFPE RNA banking according to any one of the claims 1-5, characterized in that: in the step (2), 27-33 poly (A) s are added at the end of the FFPE RNA after 10min at 37 ℃.
5. The method of claim 5 for targeted FFPE RNA banking, characterized in that: the 1 XPoly (A) Polymerase Reaction Buffer used in step (2) was 50mM Tris-HCl, 250mM NaCl, 10mM MgCl2, pH 8.1.
6. The method for targeted FFPE RNA banking of claim 1 wherein: step (3) 1stThe cDNA synthesis system comprises: the FFPE RNA fragment obtained in the step (2), buffer, dNTP, Oligo-dt30v Primer, T-Primer, reverse transcriptase and Murine RNase Inhibitor Murine RNase Inhibitor, wherein the Oligo-dt30v Primer sequence is as follows: 5 '-AAGCAGTGGTATCAACGCAGAGTACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTV-3', and the T-Primer sequence is: 5 '-AAGCAGTGGTATCACGCAGAGTACATRGG + G-3'.
Performing locked nucleic acid modification on the tail end of the T-Primer
The method for targeted FFPE RNA banking of claim 2 wherein: the Reverse Transcriptase used in the 1st cDNA synthesis system in the step (3) is Hifair IV Reverse Transcriptase Transcriptase or Hifair III Reverse Transcriptase Transcriptase.
8. The method for targeted FFPE RNA banking of claim 3, characterized in that: the reaction Buffer 5 × RT Buffer used in the 1st cDNA synthesis system in step (3) is: 250mM Tris-HCl, 375mM KCl, 28mM MgCl2, pH 7.9.
9. The method for targeted FFPE RNA banking of claim 1 wherein: the step (4) is specifically as follows: carrying out upstream specific primer design on a targeted gene, and then carrying out multiplex PCR (polymerase chain reaction) by utilizing an upstream specific primer and a downstream primer to realize amplification and enrichment of a targeted region gene, wherein the upstream specific primer is designed to be composed of a joint sequence and a specific primer, the joint primer is a sequencing primer of a sequencing platform, and the design principle of the specific primer is as follows: the length is 15-30nt, the number of continuous bases is not more than 3, the GC content is 35% -65%, the Tm value is 55-63 ℃, and the Tm of part of special regions is slightly higher or lower; the primer does not contain a self-complementary sequence, has no obvious secondary structure, and has an interval of adjacent primer recognition sites of more than 40bp and less than 100 bp; the sequence of the downstream primer is as follows: 5 '-AAGCAGTGGTATCAACGCAGAGTNNNGNNCNNNGATCGGAAGAGCACACGTCTGAACTCCAGTC-3', wherein TNNNGNNCNNN is a UMI tag.
10. The method for targeted FFPE RNA banking of claim 1 wherein: the amplification enzyme used in step (4) is: 2 × Hieff NGS HG Multiplex PCR Master Mix 2 × high GC Multiplex PCR premix, assist in san, Cat. 13283.
11. The method for targeted FFPE RNA banking of claim 1 wherein: the Library-amplifying enzyme used in step (5) was 2 Xsuper Canace II High-Fidelity Mix for Library Amplification, san Size in assist, Cat. 12621.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110627190.XA CN113355391A (en) | 2021-06-04 | 2021-06-04 | Method for establishing database by targeting FFPE RNA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110627190.XA CN113355391A (en) | 2021-06-04 | 2021-06-04 | Method for establishing database by targeting FFPE RNA |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113355391A true CN113355391A (en) | 2021-09-07 |
Family
ID=77532420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110627190.XA Pending CN113355391A (en) | 2021-06-04 | 2021-06-04 | Method for establishing database by targeting FFPE RNA |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113355391A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024222158A1 (en) * | 2023-04-27 | 2024-10-31 | 上海茵创昕生物科技有限公司 | Targeted high-throughput sequencing method for detecting splicing isoform |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102485979A (en) * | 2010-12-02 | 2012-06-06 | 深圳华大基因科技有限公司 | Formalin-fixed paraffin-embedded (FFPE) sample nucleic acid library |
CN104531862A (en) * | 2014-12-19 | 2015-04-22 | 钱学庆 | Method and primer for detecting mutation sites of all exon sequences of human BRCA1 and BRCA2 genes |
CN105658815A (en) * | 2013-10-17 | 2016-06-08 | 克隆技术实验室有限公司 | Methods for adding adapters to nucleic acids and compositions for practicing the same |
CN108251503A (en) * | 2018-01-17 | 2018-07-06 | 湖南大地同年生物科技有限公司 | A kind of method of rapid build chain specific RNA high-throughput sequencing library |
CN109402257A (en) * | 2018-11-03 | 2019-03-01 | 杭州链康医学检验实验室有限公司 | A kind of primer, method and kit for the detection of the gene whole coding sequence mutational site mankind BRCA1 and BRCA2 |
CN109517881A (en) * | 2018-06-13 | 2019-03-26 | 清华大学 | A kind of high-throughput sequencing library construction method of body fluid micro free RNA |
CN110129414A (en) * | 2019-04-28 | 2019-08-16 | 安徽鼎晶生物科技有限公司 | A kind of BRCA high-throughput sequencing library and its construction method and application |
CN110396516A (en) * | 2018-04-25 | 2019-11-01 | 武汉康测科技有限公司 | A kind of absolute quantitation transcript profile library constructing method based on peculiar identification sequence |
CN111321208A (en) * | 2020-02-14 | 2020-06-23 | 上海厦维生物技术有限公司 | Database building method based on high-throughput sequencing |
CN111826421A (en) * | 2020-07-09 | 2020-10-27 | 广州迈景基因医学科技有限公司 | PCR random primer and method for constructing target sequencing library by using same |
CN113463202A (en) * | 2020-03-31 | 2021-10-01 | 广州序科码生物技术有限责任公司 | Novel RNA high-throughput sequencing method, primer group and kit and application thereof |
CN115003867A (en) * | 2020-03-16 | 2022-09-02 | 深圳华大智造科技股份有限公司 | Construction method of sequencing library of RNA (ribonucleic acid) of sample to be detected |
-
2021
- 2021-06-04 CN CN202110627190.XA patent/CN113355391A/en active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102485979A (en) * | 2010-12-02 | 2012-06-06 | 深圳华大基因科技有限公司 | Formalin-fixed paraffin-embedded (FFPE) sample nucleic acid library |
CN105658815A (en) * | 2013-10-17 | 2016-06-08 | 克隆技术实验室有限公司 | Methods for adding adapters to nucleic acids and compositions for practicing the same |
CN104531862A (en) * | 2014-12-19 | 2015-04-22 | 钱学庆 | Method and primer for detecting mutation sites of all exon sequences of human BRCA1 and BRCA2 genes |
CN108251503A (en) * | 2018-01-17 | 2018-07-06 | 湖南大地同年生物科技有限公司 | A kind of method of rapid build chain specific RNA high-throughput sequencing library |
CN110396516A (en) * | 2018-04-25 | 2019-11-01 | 武汉康测科技有限公司 | A kind of absolute quantitation transcript profile library constructing method based on peculiar identification sequence |
CN109517881A (en) * | 2018-06-13 | 2019-03-26 | 清华大学 | A kind of high-throughput sequencing library construction method of body fluid micro free RNA |
CN109402257A (en) * | 2018-11-03 | 2019-03-01 | 杭州链康医学检验实验室有限公司 | A kind of primer, method and kit for the detection of the gene whole coding sequence mutational site mankind BRCA1 and BRCA2 |
CN110129414A (en) * | 2019-04-28 | 2019-08-16 | 安徽鼎晶生物科技有限公司 | A kind of BRCA high-throughput sequencing library and its construction method and application |
CN111321208A (en) * | 2020-02-14 | 2020-06-23 | 上海厦维生物技术有限公司 | Database building method based on high-throughput sequencing |
CN115003867A (en) * | 2020-03-16 | 2022-09-02 | 深圳华大智造科技股份有限公司 | Construction method of sequencing library of RNA (ribonucleic acid) of sample to be detected |
CN113463202A (en) * | 2020-03-31 | 2021-10-01 | 广州序科码生物技术有限责任公司 | Novel RNA high-throughput sequencing method, primer group and kit and application thereof |
CN111826421A (en) * | 2020-07-09 | 2020-10-27 | 广州迈景基因医学科技有限公司 | PCR random primer and method for constructing target sequencing library by using same |
Non-Patent Citations (2)
Title |
---|
SIMONE PICELLI: "Single-cell RNA-sequencing: The future of genome biology is now", RNA BIOLOGY, vol. 14, no. 5, 21 July 2016 (2016-07-21), pages 2 * |
纳昂达: "FFPE样本RNA靶向捕获应用指南", pages 2 - 3, Retrieved from the Internet <URL:http://mp.weixin.qq.com> * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024222158A1 (en) * | 2023-04-27 | 2024-10-31 | 上海茵创昕生物科技有限公司 | Targeted high-throughput sequencing method for detecting splicing isoform |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107922967B (en) | Methods for next generation genome walking and related compositions and kits | |
EP3555305B1 (en) | Method for increasing throughput of single molecule sequencing by concatenating short dna fragments | |
EP2898090B1 (en) | Method and kit for preparing a target rna depleted sample | |
US8329887B2 (en) | Synthesis of tagged nucleic acids | |
US8986958B2 (en) | Methods for generating target specific probes for solution based capture | |
EP3574112B1 (en) | Barcoded dna for long range sequencing | |
EP3730628B1 (en) | Polynucleotide adapter design for reduced bias | |
CN113106145B (en) | Compositions and methods for preparing nucleic acid libraries | |
CN104428415A (en) | 5' protection dependent amplification | |
CN111936635A (en) | Generation of single stranded circular DNA templates for single molecule sequencing | |
KR20170138566A (en) | Compositions and methods for constructing strand-specific cDNA libraries | |
CN112941635A (en) | Second-generation sequencing library building kit and method for improving library conversion rate | |
JP2019520839A (en) | Method for generating a single stranded circular DNA library for single molecule sequencing | |
WO2023098492A1 (en) | Sequencing library construction method and application | |
CN113355391A (en) | Method for establishing database by targeting FFPE RNA | |
CN108166069A (en) | A kind of novel methylate banking process and its application | |
CN114836411A (en) | Target gene capturing method based on CRISPR technology | |
US10954542B2 (en) | Size selection of RNA using poly(A) polymerase | |
WO2002103007A1 (en) | Method of uniformizing dna fragment contents and subtraction method | |
EP3198064B1 (en) | Methods for sample preparation | |
CN113718343A (en) | Rapid RNA library building method and kit | |
WO2024222158A1 (en) | Targeted high-throughput sequencing method for detecting splicing isoform | |
US20240336913A1 (en) | Method for producing a population of symmetrically barcoded transposomes | |
WO2024138690A1 (en) | Spatiotemporal transcriptome sequencing method, sequencing library construction method, and gene sequencing system | |
Lu et al. | Identification of full-length circular nucleic acids using long-read sequencing technologies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |